A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition
Information source: Janssen Korea, Ltd., Korea
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER) (Drug); Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER) (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Janssen Korea, Ltd., Korea Official(s) and/or principal investigator(s): Janssen Korea, Ltd., Korea Clinical Trial, Study Director, Affiliation: Janssen Korea, Ltd., Korea
Summary
The purpose of this study is to evaluate the bioequivalence of a newly developed ULTRACET
extended-release (ER) tablet of tramadol hydrochloride and acetaminophen, to the current
marketed ULTRACET ER tablet, in healthy participants under fasted condition.
Clinical Details
Official title: A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition
Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Plasma concentrations of racemic tramadol (Period 1)Plasma concentrations of acetaminophen (Period 1) Plasma concentrations of racemic tradamdol (Period 2) Plasma concentrations of acetaminophen (Period 2)
Secondary outcome: Incidence of adverse events as a measure of safety and tolerability
Eligibility
Minimum age: 20 Years.
Maximum age: 55 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Signed an informed consent document indicating they understand the purpose of and
procedures required for the study and are willing to participate
- Must agree to use an adequate contraception method as deemed appropriate by the
investigator (e. g., vasectomy, double-barrier, partner using effective contraception)
and to not donate sperm during the study and for 3 months after receiving the last
dose of study drug
- Body mass index (weight [kg]/height2 [m]2) between 18. 5 and 30 kg/m2 (inclusive), and
body weight not less than 50 kg
- Blood pressure (after the participant is sitting for 5 minutes) between 90 and 140 mm
Hg systolic, inclusive, and no higher than 90 mm Hg diastolic
- A 12-lead electrocardiogram (ECG) consistent with normal cardiac function, including
sinus rhythm, pulse rate between 45 and 90 bpm, QTc interval <= 450 ms, QRS interval
of <110 ms, PR interval <200 ms, and morphology consistent with healthy cardiac
function
Exclusion Criteria:
- History of or current clinically significant medical illness including (but not
limited to) cardiac arrhythmias or other cardiac disease, hematologic (blood)
disease, coagulation disorders (including any abnormal bleeding), lipid
abnormalities, significant lung disease (including bronchospastic respiratory
disease), diabetes mellitus, kidney or liver insufficiency, thyroid disease,
neurologic or psychiatric disease, infection, or any other illness that the
investigator considers should exclude the participant or that could interfere with
the interpretation of the study results
- Clinically significant abnormal values for hematology, clinical chemistry or
urinalysis at screening or at admission to the study center as deemed appropriate by
the investigator
- Clinically significant abnormal physical examination, vital signs or 12-lead ECG at
screening (or at admission to the study center) as deemed appropriate by the
investigator
- Use of any prescription or nonprescription medication (including vitamins and herbal
supplements), except for oral contraceptives and hormonal replacement therapy within
14 days before the first dose of the study drug is scheduled
- History of, or reason to believe a participant has a history of, drug or alcohol
abuse within the past 5 years
Locations and Contacts
Seoul, Korea, Republic of
Additional Information
A Single-Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Conditions
Starting date: December 2012
Last updated: February 7, 2014
|